MedTrace Logo

A Retrospective Study of Anti-Vascular Endothelial Growth Factor (VEGF) Injections for Retinal Vein Occlusion or Diabetic Macular Edema

NCT01918371 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 323

Last updated 2019-04-18

Study results available
· View outcomes & findings →

Summary

This retrospective data review study will evaluate anti-VEGF injections for retinal vein occlusion (RVO) or diabetic macular edema (DME).

Conditions

  • Retinal Vein Occlusion
  • Macular Edema

Interventions

DRUG

Anti-VEGF

Patients with retinal vein occlusion or diabetic macular edema receiving anti-VEGF injection(s) in accordance with standard of care practices. This is a retrospective chart review study.

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Medical Director · Allergan

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-08-02
Primary Completion
2014-09-04
Completion
2014-09-04

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01918371 on ClinicalTrials.gov